Q32 Bio Inc.
QTTB
$2.37
-$0.20-7.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -14.66M | -12.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -14.66M | -12.80M |
| Cost of Revenue | 25.44M | 25.54M | 25.43M | 23.23M | 16.35M |
| Gross Profit | -25.44M | -25.54M | -25.43M | -37.89M | -29.15M |
| SG&A Expenses | 17.56M | 18.06M | 17.96M | 16.79M | 14.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.82M | 62.56M | 66.10M | 62.72M | 53.57M |
| Operating Income | -53.82M | -62.56M | -66.10M | -77.39M | -66.37M |
| Income Before Tax | -53.91M | -61.40M | -49.34M | -60.36M | -56.73M |
| Income Tax Expenses | -1.60M | -1.60M | -1.60M | 253.00K | 318.00K |
| Earnings from Continuing Operations | -52.30 | -59.79 | -47.73 | -60.61 | -57.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.30M | -59.79M | -47.73M | -60.61M | -57.05M |
| EBIT | -53.82M | -62.56M | -66.10M | -77.39M | -66.37M |
| EBITDA | -53.36M | -62.08M | -65.62M | -76.89M | -65.88M |
| EPS Basic | -4.30 | -4.95 | -3.01 | -78.22 | -117.29 |
| Normalized Basic EPS | -3.50 | -3.90 | -2.74 | -37.48 | -61.82 |
| EPS Diluted | -4.31 | -4.95 | -10.37 | -85.59 | -124.65 |
| Normalized Diluted EPS | -3.50 | -3.90 | -3.11 | -37.86 | -62.19 |
| Average Basic Shares Outstanding | 48.65M | 48.42M | 37.22M | 25.39M | 13.66M |
| Average Diluted Shares Outstanding | 48.65M | 48.42M | 38.56M | 26.73M | 15.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |